America’s largest pharmaceutical distributor slips two spots on the Global 500 this year, but the continued strength of its distribution business—serving as the middleman between manufacturers and pharmacies—lifted revenues 4.9%. The acquisition of Rexall Health powered some of that growth as did trends like the nation’s climbing drug prices and rising drug utilization rates. McKesson also moved ahead with its plan to divest its technology businesses in deals with Change Healthcare and Allscripts. The company, along with the country’s other large drug distributors, remains a target of litigation over its alleged role in the nation’s opioid epidemic.
Looking for leads, investment insights, or competitive intelligence?
News about McKesson
John Hammergren is retiring after nearly two decades on the job.
The decision to sue is seen as an acknowledgment opioid makers won’t get serious about settling until the cases go to trial.
The president's drug price proposals didn't shake big pharma and other health care companies.
Attorney General Jeff Sessions announced a "statement of intent" to prop up suits against opioid makers and distributors.
Sparking a selloff in the shares of a host of health care-related companies.